Shree Ganesh Remedies Ltd
P&L
Quarterly Consolidated
vs Q2 FY26
Shree Ganesh Remedies Limited Reports Q3 & 9MFY26 Results with 22% YoY Revenue Decline
23 Jan 2026 · 23 Jan, 9:05 pm
Summary
Shree Ganesh Remedies Limited, a leading player in the chemical manufacturing industry, reported its financial results for Q3 & IMFY26. The company witnessed a 22% YoY decline in revenue due to delays in shipments, challenging demand environment in Europe, and heightened competitive intensity. Despite this, the company remains focused on disciplined growth, strengthening its platform for scale-up, and delivering sustainable profitability through the cycle.
Key Highlights
- 1
22% YoY decline in revenue in Q3FY26
- 2
43% YoY decline in PAT in Q3FY26
- 3
32% YoY decline in EBITDA in Q3FY26
- 4
31.9% EBITDA margins in Q3FY26
- 5
10-12% of the reported topline for the quarter deferred to Q4FY26
- 6
FY26 is a year of consolidation
- 7
New pilot facility commissioned and operational
- 8
Expansion programme for Block 7 progressing as planned
- 9
CRAMS engagement with Japanese client advancing positively
- 10
Gradual improvement in business momentum expected in FY27
- 11
27.72 Cr. Revenue from Speciality Chemicals in 9MFY26
- 12
3.10 Cr. PAT in Q3FY26
Management Comments
Mr. Gunjan Kothia
Promoter, Head of Business Development & Innovation
Q3FY26 was impacted by three key factors... Despite this near-term pressure, our long-term outlook remains intact... FY26 is a year of consolidation... The team remains focused on driving volume improvement to offset softer realisations and sustain sales performance at levels comparable to the previous year... Operationally, progress remains steady... Looking ahead to FY27, we expect a gradual improvement in business momentum... We remain focused on disciplined growth, strengthening our platform for scale-up, and delivering sustainable profitability through the cycle.
Informational and educational content only. Not investment advice.